A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancer.
Athira Narayan, Ryan C Leibrandt, Joyce S Lee...
https://pubmed.ncbi.nlm.nih.gov/42226594/Actively Recruiting
Led by University of California, Davis · Updated on 2026-03-13
12
Participants Needed
1
Research Sites
26 weeks
Total Duration
Researchers are evaluating the safety, tolerability, and effectiveness of PLZ4-coated paclitaxel-loaded micelles PPM in treating patients with non-muscle invasive bladder cancer that has returned after improvement or has not responded to prior treatment. This phase I trial focuses on a nanoparticle designed to specifically target and deliver paclitaxel to bladder tumor cells. The study aims to understand how well this targeted treatment can work for patients with recurrent or refractory bladder cancer. Participants receive PPM through a bladder instillation over one hour once a week for six weeks, provided there is no disease progression or unacceptable side effects. Before and during the trial, patients undergo imaging tests like CT, MRI, or PET scans, along with cystoscopy and biopsy to monitor the bladder tumors. Blood samples are also collected throughout the study to assess health and treatment effects. After completing the treatment phase, patients are followed up at 3 weeks, 6 weeks, and then every 3 months for two years as part of standard care. Researchers evaluate tumor response six weeks after treatment ends and track event-free survival over 12 months, including monitoring for tumor progression, recurrence, or additional treatments. Safety is closely monitored from the first dose until 12 months after the last dose to understand any treatment-related side effects.
CONDITIONS
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
O
Office of Clinical Research
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, Davis
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | PPM (investigational) | Radical cystectomy (current standard) |
|---|---|---|
| What it is | An investigational intravesical therapy delivering paclitaxel in PLZ4‑coated micelles directly into the bladder. | Surgical removal of the bladder (radical cystectomy) remains the established standard treatment for BCG‑unresponsive NMIBC. |
| Role in the trial | This was the single investigational treatment given to all enrolled participants. | Not included in the trial but represents the alternative definitive treatment outside the study. |
| Primary use | To treat patients with BCG‑unresponsive NMIBC who decline or are unfit for radical cystectomy. | Definitive surgical treatment for BCG‑unresponsive NMIBC, aiming to remove tumor and prevent progression. |
| How it is given or performed | Delivered directly into the bladder via intravesical instillation of paclitaxel‑loaded micelles coated with PLZ4. | Performed as surgical removal of the bladder under general anesthesia. |
| Evidence status | Clinical evidence limited to this single‑group study; efficacy remains to be established. | Long‑standing evidence supports durable disease control with radical cystectomy in this setting. |
| Important limitations | Single‑arm design lacks direct comparison; safety and long‑term outcomes uncertain. | Surgery carries significant morbidity and may be declined or unsuitable for some patients. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
/CT, MRI, or PET, and cystoscopy with biopsy at screening.
Duration - 6 weeks
Participants receive PLZ4-coated paclitaxel loaded micelles intravesically over 1 hour once a week for 6 weeks if there is no disease progression or unacceptable toxicity.
Weekly visits for 6 weeks (in-person)
Duration - 2 years
After completing treatment, participants are followed up at 3 weeks, 6 weeks, and then every 3 months per standard of care for 2 years to monitor safety and tumor response.
Follow-up visits at 3 weeks, 6 weeks, and every 3 months thereafter
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Athira Narayan, Ryan C Leibrandt, Joyce S Lee...
https://pubmed.ncbi.nlm.nih.gov/42226594/University of California, Davis
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor